$TBPH
Theravance Biopharma Inc

2021 Q4 Form 10-Q Financial Statement

#000155837021014907 Filed on November 08, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $14.95M $13.19M $18.26M
YoY Change -20.2% -27.73% 46.91%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $39.11M $21.30M $27.50M
YoY Change 29.93% -22.55% 7.33%
% of Gross Profit
Research & Development $31.23M $43.74M $67.37M
YoY Change -52.11% -35.08% 29.54%
% of Gross Profit
Depreciation & Amortization $1.361M $1.625M $1.360M
YoY Change -3.48% 19.49% -24.86%
% of Gross Profit
Operating Expenses $71.11M $66.81M $94.87M
YoY Change -25.32% -29.58% 22.21%
Operating Profit -$56.17M -$53.62M -$76.62M
YoY Change -26.57% -30.02% 17.51%
Interest Expense $23.98M $11.74M $11.57M
YoY Change 157.87% 1.46% 43.44%
% of Operating Profit
Other Income/Expense, Net -$166.0K $1.235M
YoY Change -113.44% -40.88%
Pretax Income -$32.19M -$35.32M -$73.55M
YoY Change -52.11% -51.99% 14.95%
Income Tax -$151.0K -$7.000K $93.00K
% Of Pretax Income
Net Earnings -$32.03M -$35.31M -$73.64M
YoY Change -45.18% -52.06% 26.03%
Net Earnings / Revenue -214.33% -267.61% -403.37%
Basic Earnings Per Share -$0.43 -$0.48 -$1.16
Diluted Earnings Per Share -$0.43 -$0.48 -$1.16
COMMON SHARES
Basic Shares Outstanding 73.70M 73.57M 63.30M
Diluted Shares Outstanding 73.57M 63.30M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $173.5M $216.2M $358.3M
YoY Change -40.79% -39.66% 12.1%
Cash & Equivalents $89.96M $121.4M $93.28M
Short-Term Investments $83.51M $94.79M $265.1M
Other Short-Term Assets $18.81M $23.19M $31.10M
YoY Change -38.74% -25.45% 113.01%
Inventory
Prepaid Expenses
Receivables $14.07M $14.00M $12.40M
Other Receivables $43.53M $43.77M $48.90M
Total Short-Term Assets $249.9M $297.2M $450.7M
YoY Change -36.47% -34.07% 26.73%
LONG-TERM ASSETS
Property, Plant & Equipment $13.66M $16.00M $15.43M
YoY Change -16.84% 3.71% 26.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $67.54M $45.09M $0.00
YoY Change 429.7% -100.0%
Other Assets $3.228M $3.297M $810.0K
YoY Change 31.7% 307.04% -37.93%
Total Long-Term Assets $124.9M $105.9M $61.46M
YoY Change 65.02% 72.36% -31.47%
TOTAL ASSETS
Total Short-Term Assets $249.9M $297.2M $450.7M
Total Long-Term Assets $124.9M $105.9M $61.46M
Total Assets $374.8M $403.1M $512.2M
YoY Change -20.09% -21.3% 15.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.098M $8.900M $6.442M
YoY Change -54.27% 38.16% -26.06%
Accrued Expenses $38.45M $41.75M $79.60M
YoY Change -55.24% -47.55% 37.95%
Deferred Revenue $98.00K $2.902M $18.20M
YoY Change -99.15% -84.06% -46.06%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $16.94M $12.53M $0.00
YoY Change -12.23% -100.0%
Total Short-Term Liabilities $58.59M $66.08M $104.3M
YoY Change -52.59% -36.62% -4.18%
LONG-TERM LIABILITIES
Long-Term Debt $599.4M $603.3M $611.2M
YoY Change -0.07% -1.29% 36.55%
Other Long-Term Liabilities $2.420M $2.609M $9.704M
YoY Change 32.02% -73.11% 9.03%
Total Long-Term Liabilities $2.420M $2.609M $9.704M
YoY Change 32.02% -73.11% 9.03%
TOTAL LIABILITIES
Total Short-Term Liabilities $58.59M $66.08M $104.3M
Total Long-Term Liabilities $2.420M $2.609M $9.704M
Total Liabilities $61.01M $68.69M $114.0M
YoY Change -51.35% -39.73% -3.18%
SHAREHOLDERS EQUITY
Retained Earnings -$1.726B -$1.694B -$1.468B
YoY Change 13.06% 15.38% 24.11%
Common Stock $1.000K $1.000K $1.000K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$338.6M -$323.6M -$261.5M
YoY Change
Total Liabilities & Shareholders Equity $374.8M $403.1M $512.2M
YoY Change -20.09% -21.3% 15.01%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$32.03M -$35.31M -$73.64M
YoY Change -45.18% -52.06% 26.03%
Depreciation, Depletion And Amortization $1.361M $1.625M $1.360M
YoY Change -3.48% 19.49% -24.86%
Cash From Operating Activities -$42.43M -$45.45M -$77.03M
YoY Change -34.64% -41.0% 72.6%
INVESTING ACTIVITIES
Capital Expenditures -$444.0K -$1.039M -$2.050M
YoY Change -64.48% -49.32% 2828.57%
Acquisitions
YoY Change
Other Investing Activities $11.27M -$34.75M $68.58M
YoY Change -78.99% -150.68% -390.84%
Cash From Investing Activities $10.82M -$35.79M $66.54M
YoY Change -79.33% -153.79% -381.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 149.0K -2.286M -970.0K
YoY Change -80.13% 135.67% 646.15%
NET CHANGE
Cash From Operating Activities -42.43M -45.45M -77.03M
Cash From Investing Activities 10.82M -35.79M 66.54M
Cash From Financing Activities 149.0K -2.286M -970.0K
Net Change In Cash -31.46M -83.53M -11.46M
YoY Change 166.62% 628.84% -83.25%
FREE CASH FLOW
Cash From Operating Activities -$42.43M -$45.45M -$77.03M
Capital Expenditures -$444.0K -$1.039M -$2.050M
Free Cash Flow -$41.99M -$44.41M -$74.98M
YoY Change -34.05% -40.77% 68.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61881000
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Entity Central Index Key
EntityCentralIndexKey
0001583107
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.55
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73574000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63303000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67945000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73574000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63303000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67945000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61881000
CY2021Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64328000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64328000
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73698000
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.55
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36033
dei Entity Registrant Name
EntityRegistrantName
THERAVANCE BIOPHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
KY
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1226628
dei Entity Address Address Line1
EntityAddressAddressLine1
PO Box 309
dei Entity Address Address Line2
EntityAddressAddressLine2
Ugland House, South Church Street
dei Entity Address City Or Town
EntityAddressCityOrTown
George Town, Grand Cayman
dei Entity Address Country
EntityAddressCountry
KY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
KY1-1104
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
808-6000
dei Security12b Title
Security12bTitle
Ordinary Share $0.00001 Par Value
dei Trading Symbol
TradingSymbol
TBPH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
73698388
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
121424000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81467000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
94789000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
211474000
CY2021Q3 tbph Receivables From Collaboration Partners
ReceivablesFromCollaborationPartners
14001000
CY2020Q4 tbph Receivables From Collaboration Partners
ReceivablesFromCollaborationPartners
15868000
CY2021Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
43773000
CY2020Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
53799000
CY2021Q3 tbph Prepaid Clinical And Development Services
PrepaidClinicalAndDevelopmentServices
13242000
CY2020Q4 tbph Prepaid Clinical And Development Services
PrepaidClinicalAndDevelopmentServices
20374000
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
9943000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
10359000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
297172000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
393341000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16003000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16422000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
40718000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
43260000
CY2021Q3 us-gaap Equity Method Investments
EquityMethodInvestments
45086000
CY2020Q4 us-gaap Equity Method Investments
EquityMethodInvestments
12750000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
833000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
833000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3297000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2451000
CY2021Q3 us-gaap Assets
Assets
403109000
CY2020Q4 us-gaap Assets
Assets
469057000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
8900000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6775000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8635000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
35238000
CY2021Q3 tbph Accrued Clinical And Development Expenses Current
AccruedClinicalAndDevelopmentExpensesCurrent
20607000
CY2020Q4 tbph Accrued Clinical And Development Expenses Current
AccruedClinicalAndDevelopmentExpensesCurrent
28799000
CY2021Q3 tbph Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
3854000
CY2020Q4 tbph Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
6048000
CY2021Q3 us-gaap Interest Payable Current
InterestPayableCurrent
5808000
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
3974000
CY2021Q3 tbph Non Recourse Debt Due2035 Current
NonRecourseDebtDue2035Current
12530000
CY2020Q4 tbph Non Recourse Debt Due2035 Current
NonRecourseDebtDue2035Current
19334000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1016000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9867000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2902000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11523000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1830000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2013000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
66082000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
123571000
CY2021Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
227767000
CY2020Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
226963000
CY2021Q3 tbph Non Recourse Debt Due2035 Noncurrent
NonRecourseDebtDue2035Noncurrent
375570000
CY2020Q4 tbph Non Recourse Debt Due2035 Noncurrent
NonRecourseDebtDue2035Noncurrent
372873000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
54353000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
47220000
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
320000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
348000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2609000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1833000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
230000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
230000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73698000
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1370402000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1222818000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
14000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
47000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1694009000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1526617000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-323592000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-303751000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
403109000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
469057000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13194000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18257000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
40365000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
53127000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43739000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
67371000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
162431000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
195788000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21299000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
27501000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
77780000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
78606000
CY2021Q3 us-gaap Restructuring Charges
RestructuringCharges
1771000
us-gaap Restructuring Charges
RestructuringCharges
1771000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
66809000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
94872000
us-gaap Operating Expenses
OperatingExpenses
241982000
us-gaap Operating Expenses
OperatingExpenses
274394000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-53615000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-76615000
us-gaap Operating Income Loss
OperatingIncomeLoss
-201617000
us-gaap Operating Income Loss
OperatingIncomeLoss
-221267000
CY2021Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
30208000
CY2020Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
13403000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
68681000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
48299000
CY2021Q3 us-gaap Interest Expense
InterestExpense
11742000
CY2020Q3 us-gaap Interest Expense
InterestExpense
11573000
us-gaap Interest Expense
InterestExpense
35227000
us-gaap Interest Expense
InterestExpense
32905000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-15464000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-166000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1235000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
771000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2033000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35315000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-73550000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-167392000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-219304000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
93000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
279000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-35308000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-73643000
us-gaap Net Income Loss
NetIncomeLoss
-167392000
us-gaap Net Income Loss
NetIncomeLoss
-219583000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-158000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-33000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-23000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35302000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-73801000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-167425000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-219606000
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.55
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73574000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63303000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67945000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61881000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14370000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15564000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
45143000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
47425000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-300374000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14370000
CY2021Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2286000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-35308000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-323592000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-303751000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
108180000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2862000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
45143000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
8606000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-33000
us-gaap Net Income Loss
NetIncomeLoss
-167392000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-323592000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-202336000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15564000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
24000
CY2020Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
987000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-158000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-73643000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-261536000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-223840000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
139915000
us-gaap Net Income Loss
NetIncomeLoss
-167392000
us-gaap Net Income Loss
NetIncomeLoss
-219583000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
4551000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
5394000
tbph Amortization And Accretion Income
AmortizationAndAccretionIncome
-9000
tbph Amortization And Accretion Income
AmortizationAndAccretionIncome
1023000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2545000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
47425000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
960000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
8935000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-23000
us-gaap Net Income Loss
NetIncomeLoss
-219583000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-261536000
us-gaap Share Based Compensation
ShareBasedCompensation
45143000
us-gaap Share Based Compensation
ShareBasedCompensation
47425000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2758000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2213000
tbph Gain Loss On Modification Of Lease
GainLossOnModificationOfLease
1863000
tbph Equity Method Investments Undistributed Earnings
EquityMethodInvestmentsUndistributedEarnings
22310000
tbph Equity Method Investments Undistributed Earnings
EquityMethodInvestmentsUndistributedEarnings
20337000
tbph Interest Shortfall On2035 Notes
InterestShortfallOn2035Notes
5713000
tbph Interest Shortfall On2035 Notes
InterestShortfallOn2035Notes
10144000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-15464000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-35000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
42000
tbph Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-1867000
tbph Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-9597000
tbph Increase Decrease In Prepaid Clinical And Development Services
IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices
-7132000
tbph Increase Decrease In Prepaid Clinical And Development Services
IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices
18025000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
99000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
2274000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1006000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-578000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2206000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2133000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-36573000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-178000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1834000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
132000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-8648000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-19382000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
443000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
2021000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
776000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
265000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-165424000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-185478000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
2962000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
5372000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
104774000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
337556000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
221400000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
281318000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
19928000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
6000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
35000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
113670000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41647000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
108180000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
139915000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
380000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
5326000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
10730000
us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
11470000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
235347000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2862000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2545000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
960000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
8606000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
8935000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
91711000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
262342000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
39957000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
35218000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82300000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58897000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122257000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94115000
us-gaap Interest Paid Net
InterestPaidNet
25967000
us-gaap Interest Paid Net
InterestPaidNet
20287000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-3814000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
14000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</p>
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
185614000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
10000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
185624000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
211427000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
53000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-35308000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-73643000
us-gaap Net Income Loss
NetIncomeLoss
-167392000
us-gaap Net Income Loss
NetIncomeLoss
-219583000
CY2021Q3 tbph Weighted Average Number Of Shares Outstanding Before Forfeitures
WeightedAverageNumberOfSharesOutstandingBeforeForfeitures
73574000
CY2020Q3 tbph Weighted Average Number Of Shares Outstanding Before Forfeitures
WeightedAverageNumberOfSharesOutstandingBeforeForfeitures
63717000
tbph Weighted Average Number Of Shares Outstanding Before Forfeitures
WeightedAverageNumberOfSharesOutstandingBeforeForfeitures
68021000
tbph Weighted Average Number Of Shares Outstanding Before Forfeitures
WeightedAverageNumberOfSharesOutstandingBeforeForfeitures
62361000
CY2020Q3 tbph Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture
IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture
-414000
tbph Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture
IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture
-76000
tbph Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture
IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture
-480000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73574000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63303000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67945000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61881000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.55
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15576000
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14739000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14983000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13242000
CY2018Q1 tbph Profit Loss Percentage As Per Collaboration Agreement
ProfitLossPercentageAsPerCollaborationAgreement
0.33
tbph Profit Loss Percentage As Per Collaboration Agreement
ProfitLossPercentageAsPerCollaborationAgreement
0.35
CY2021Q3 tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
3301000
CY2020Q3 tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
1404000
tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
5987000
tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
5796000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
121424000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93282000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
833000
CY2020Q3 us-gaap Restricted Cash
RestrictedCash
833000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122257000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94115000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
211474000
tbph Marketable Securities Maximum Contractual Maturity Period
MarketableSecuritiesMaximumContractualMaturityPeriod
P6M
tbph Marketable Securities Average Contractual Maturity Period
MarketableSecuritiesAverageContractualMaturityPeriod
P1M
CY2021Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
44420000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
6000
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
44420000
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
6000
CY2021Q3 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
0
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
19900000
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
615867000
CY2021Q3 tbph Area Of Leased Space
AreaOfLeasedSpace
170000
tbph Number Of Building Leased
NumberOfBuildingLeased
2
CY2021Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
8000
CY2021Q3 tbph Increase Decrease In Operating Lease Asset
IncreaseDecreaseInOperatingLeaseAsset
-1100000
CY2021Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3000000.0
tbph Gain Loss On Modification Of Lease
GainLossOnModificationOfLease
1900000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries
DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries
0
CY2021Q3 tbph Area Of Property Subleased
AreaOfPropertySubleased
21000
CY2021Q3 tbph Sublease Monthly Base Rent
SubleaseMonthlyBaseRent
100000
CY2021Q3 tbph Sublease Percentage Of Increase In Annual Base Rent
SubleasePercentageOfIncreaseInAnnualBaseRent
0.03
CY2021Q2 us-gaap Share Price
SharePrice
15.00
CY2021Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7705000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
115600000
CY2021Q3 tbph Percentage Of Reduction In Workforce
PercentageOfReductionInWorkforce
0.75
CY2021Q3 tbph Percentage Of Reduction In Workforce
PercentageOfReductionInWorkforce
0.75
CY2021Q3 us-gaap Severance Costs1
SeveranceCosts1
1771000
us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
1771000
CY2021Q3 us-gaap Restructuring Reserve
RestructuringReserve
1771000
us-gaap Restructuring Charges
RestructuringCharges
1800000

Files In Submission

Name View Source Status
0001558370-21-014907-index-headers.html Edgar Link pending
0001558370-21-014907-index.html Edgar Link pending
0001558370-21-014907.txt Edgar Link pending
0001558370-21-014907-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tbph-20210930.xsd Edgar Link pending
tbph-20210930x10q.htm Edgar Link pending
tbph-20210930x10q_htm.xml Edgar Link completed
tbph-20210930xex31d1.htm Edgar Link pending
tbph-20210930xex31d2.htm Edgar Link pending
tbph-20210930xex32.htm Edgar Link pending
tbph-20210930_cal.xml Edgar Link unprocessable
tbph-20210930_def.xml Edgar Link unprocessable
tbph-20210930_lab.xml Edgar Link unprocessable
tbph-20210930_pre.xml Edgar Link unprocessable